March 12, 2010
Otsuka Pharmaceutical Co., Ltd.
FerriSeltz® powder 20%, MRI Oral GI Contrast Agent, Receives Additional Approval for GI Negative Imaging in Cholangiopancreatography
Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) today announced that it acquired additional approval of indications, dosage and administration for the MRI oral GI contrast agent, FerriSeltz® powder 20%, for GI negative imaging in cholangiopancreatography in abdominal magnetic resonance and computed tomography on March 12, 2010.
Information in this news release was current as of the original release date.